KYSE-30 Xenograft Model Service for Esophageal Squamous Cell Carcinoma (ESCC)

The KYSE-30 xenograft model represents a well-established and clinically relevant platform for evaluating therapeutic candidates against esophageal squamous cell carcinoma (ESCC), faithfully recapitulating the histopathological and molecular features of the parental tumor. Alfa Cytology provides a comprehensive KYSE-30 Xenograft Model Service for Esophageal Squamous Cell Carcinoma (ESCC), delivering validated preclinical tumor models with robust growth kinetics, standardized endpoints, and customizable study designs to accelerate your oncology drug development pipeline.

Overview of KYSE-30 Xenograft Model for Esophageal Squamous Cell Carcinoma (ESCC)

KYSE-30 is a well-differentiated human esophageal squamous cell carcinoma (ESCC) cell line originally established from the mucosal surface of a primary tumor resected from an untreated 64-year-old male patient. As part of the extensively characterized KYSE series, this cell line exhibits a rapid doubling time of approximately 20.8 hours during exponential growth, adherent polygonal epithelioid morphology with long pseudopods, and robust tumorigenicity in immunocompromised hosts. Genetically, KYSE-30 harbors a p53 mutation at the splice acceptor site of intron 6, a 12-fold amplification of c-erbB (HER2), and expresses exceptionally high levels of epidermal growth factor receptors (1.2 x 10^7 sites per cell), making it particularly relevant for studies targeting receptor tyrosine kinase signaling pathways in ESCC.

When propagated as a xenograft, KYSE-30 cells form subcutaneous tumors that retain the histological architecture of well-differentiated squamous cell carcinoma, including keratin pearl formation and intercellular bridges characteristic of the original lesion. The model demonstrates consistent engraftment rates, predictable tumor growth kinetics, and responsiveness to standard-of-care chemotherapeutic agents, establishing it as a reliable preclinical surrogate for evaluating novel therapeutic modalities---including targeted small molecules, immune-oncology combinations, and radiotherapy sensitizers---in the context of esophageal malignancy.

Figure 1. Overview of the KYSE-30 subcutaneous xenograft workflow in J:NU mice. (Solopov, Pavel A., et al., 2026)

Cell Line Information: KYSE-30

KYSE-30 was established through initial transplantation of tumor fragments to athymic nude mice followed by in vitro adaptation, a methodology that preserves tumor heterogeneity and stromal interactions. The cell line has been extensively profiled across multiple molecular platforms and is cataloged in the Cancer Cell Line Encyclopedia (CCLE) and other international repositories.

Our Services

Alfa Cytology leverages the KYSE-30 cell line to generate high-fidelity xenograft models that meet rigorous preclinical standards, offering end-to-end services spanning cell line authentication, tumor implantation, in-life monitoring, and comprehensive endpoint analysis. Our experienced oncology team ensures consistent model performance, reproducible data generation, and seamless integration with your downstream pharmacology and translational research workflows, enabling confident decision-making at every stage of candidate development.

Workflow of KYSE-30 Xenograft Model Construction

The construction of KYSE-30 xenograft models follows a standardized, quality-controlled workflow designed to ensure reproducible tumor engraftment, consistent growth kinetics, and reliable pharmacological readouts. Each stage incorporates stringent quality assurance measures to maintain model integrity and data validity throughout the study duration.

1. Cell Line Expansion and Quality Control: KYSE-30 cells are expanded from authenticated master cell banks under aseptic conditions, verified for mycoplasma negativity, species identity, and short tandem repeat (STR) profile concordance prior to implantation.
2. Host Selection and Acclimatization: Female athymic nude mice (Hsd:Athymic Nude-Foxn1) aged 6-8 weeks are housed in barrier-controlled environments with standardized diet and light cycles, undergoing a minimum 5-day acclimatization period before tumor cell inoculation.
3. Cell Preparation and Matrigel Mixing: Exponentially growing KYSE-30 cells are harvested at 80-90% confluence, washed in serum-free medium, and resuspended at a concentration of 5.0 x 10^6 cells per 100 microL in a 1:1 mixture of serum-free RPMI 1640 and Growth Factor-Reduced (GFR) Matrigel to enhance engraftment efficiency.
4. Subcutaneous Implantation: The cell suspension is injected subcutaneously into the right flank of each mouse using a 25-gauge needle; tumor palpability is typically observed within 7-10 days post-inoculation, with caliper measurements commencing once tumors reach ~50-100 mm^3.
5. In-Life Monitoring and Tumor Assessment: Body weights and tumor dimensions (length x width) are recorded twice weekly; tumor volume is calculated using the modified ellipsoid formula (L x W^2 x 0.5), with animals randomized into treatment cohorts when tumors reach the predetermined target volume.
6. Endpoint Collection and Histopathological Analysis: At study termination, tumors are excised, weighed, and processed for formalin-fixed paraffin-embedded (FFPE) histology, immunohistochemistry (IHC), and molecular profiling; blood and organ samples are collected for toxicity and pharmacokinetic assessment.

Figure 2: Schematic workflow illustrating the derivation and construction of the KYSE-30 Xenograft Model at Alfa Cytology.

Case Study-KYSE-30 Xenograft Model Development

In a representative preclinical engagement, KYSE-30 xenografts were established to evaluate the efficacy of a novel receptor tyrosine kinase inhibitor targeting the EGFR/HER2 axis. Tumors were allowed to reach a mean volume of approximately 150-200 mm^3 before randomization into vehicle control and treatment arms. Compound administration was performed via oral gavage on a twice-daily schedule for 21 consecutive days. Treatment resulted in a statistically significant reduction in tumor growth rate compared to the control cohort, with corresponding decreases in Ki-67 proliferation index and phospho-ERK expression observed in post-treatment tumor sections. Body weight trajectories remained stable throughout the dosing period, indicating acceptable tolerability. This case study demonstrates the utility of the KYSE-30 model for generating pharmacodynamic and efficacy data to support candidate prioritization and IND-enabling studies, with full datasets available upon request for client-specific evaluation.

Why Choose Alfa Cytology?

Alfa Cytology combines deep scientific expertise in oncology model development with operational excellence to deliver KYSE-30 xenograft studies that meet the highest standards of preclinical rigor and regulatory expectation. Our integrated platform ensures seamless execution from study design to data delivery.

• Rigorous cell line authentication via STR profiling and mycoplasma screening guarantees model integrity and traceability for every study.
• Standardized tumor implantation protocols with documented engraftment rates and growth kinetics reduce experimental variability and accelerate study initiation.
• Flexible study designs accommodate single-agent, combination, dose-response, and scheduling optimization studies tailored to your program requirements.
• Comprehensive endpoint analysis including tumor biobanking, IHC, flow cytometry, and molecular profiling provides mechanistic insights beyond standard efficacy readouts.
• Dedicated project management and transparent reporting ensure real-time visibility into study progress with scheduled interim data releases.
• Competitive timelines and cost-efficient operations enable rapid iteration between in vivo and in vitro datasets without compromising data quality.

Contact Us

Ready to advance your ESCC therapeutic program with a validated KYSE-30 xenograft model? Please reach out to us today via our inquiry form or email to learn more about our KYSE-30 Xenograft Model services.

For research use only. Not intended for any clinical use.